噁唑烷酮-喹诺酮杂合物的研究进展

doi:10.11843/j.issn.0366-6964.2018.01.002

摘要/Abstract

摘要：

由于细菌耐药现象的日益严重，近些年来对新型抗菌药的需求不断增长。利用拼合原理将两种药物通过一定的方式连接而成的多靶点杂合物，为扩大药物的抗菌谱、增强药物对耐药菌的有效性及降低耐药性的出现提供了可能，已成为研发新型抗菌药物的一种新策略。与此同时，噁唑烷酮类和喹诺酮类抗菌药以其独特的作用机制和抗菌谱互补的特点吸引了研究者的关注，因此他们将这两类抗菌药物的药效基团进行拼合形成了一系列的噁唑烷酮-喹诺酮杂合物，并已表明它们对多种敏感和耐药菌株均有活性。本文就此类杂合物的设计合成、抗菌活性及目前处于临床研究阶段的噁唑烷酮-喹诺酮杂合物——咔哒唑胺的研究进展作一综述。

Abstract:

Due to the increasing severity of bacterial drug resistance, the demand for novel antimicrobial agents has been growing in recent years. The multi-target hybrid which combines two kinds of drugs by a certain way provides the possibility for expanding the antibacterial spectrum, enhancing the activity against drug-resistant bacteria and reducing the frequency of bacterial resistance, and has become a new strategy to the research and development of novel antimicrobial agents. Meanwhile, oxazolidinones and quinolones with their unique mechanism of action and the complementary antibacterial spectrum attract the attention of researchers. Oxazolidinone-quinolone hybrids incorporating oxazolidinone and quinolone pharmacophores have been synthesized and shown to be active against a variety of susceptible and resistant Gram-positive and Gram-negative bacteria. In the present paper, the design, synthesis and antimicrobial activities of oxazolidinone-quinolone hybrids, and the research progress of cadazolid, a oxazolidinone-quinolone hybrid which is currently at the stage of clinical trials, are reviewed.

中图分类号:

R978.1

刘利利, 张继瑜. 噁唑烷酮-喹诺酮杂合物的研究进展[J]. 畜牧兽医学报, 2018, 49(1): 10-17.

LIU Li-li, ZHANG Ji-yu. Advances on Oxazolidinone-quinolone Hybrids[J]. ACTA VETERINARIA ET ZOOTECHNICA SINICA, 2018, 49(1): 10-17.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: https://www.xmsyxb.com/CN/10.11843/j.issn.0366-6964.2018.01.002

https://www.xmsyxb.com/CN/Y2018/V49/I1/10

参考文献

[1] BAUER P R, SAMPATHKUMAR P. Methicillin-resistant Staphylococcus aureus infection in ICU:What is the best prevention strategy?[J]. Crit Care Med, 2017, 45(8):1413-1414.
[2] ZAJONZ D, WUTHE L, RODLOFF A C, usw. Infektionen von Hüft-und Knieendoprothesen[J]. Der Chirurg, 2016, 87(4):332-339.
ZAJONZ D, WUTHE L, RODLOFF A C, et al. Infections of the hip and knieendoprothesen[J]. The Surgeon, 2016, 87(4):332-339.(in German)
[3] OKADA T, SATO Y, TOYONAGA Y, et al. Nationwide survey of Streptococcus pneumoniae drug resistance in the pediatric field in Japan[J]. Pediatr Int, 2016, 58(3):192-201.
[4] MILLER W R, MURRAY B E, RICE L B, et al. Vancomycin-resistant enterococci:therapeutic challenges in the 21st century[J]. Infect Dis Clin North Am, 2016, 30(2):415-439.
[5] POKROVSKAYA V, BAASOV T. Dual-acting hybrid antibiotics:a promising strategy to combat bacterial resistance[J]. Expert Opin Drug Discov, 2010, 5(9):883-902.
[6] DALY J S, ELIOPOULOS G M, REISZNER E, et al. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds[J]. J Antimicrob Chemother, 1988, 21(6):721-730.
[7] YAGI B H, ZURENKO G E. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria[J]. Anaerobe, 1997, 3(5):301-306.
[8] SENIOR K. FDA approves first drug in new class of antibiotics[J]. Lancet, 2000, 355(9214):1523.
[9] IM W B, CHOI S H, PARK J Y, et al. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent[J]. Eur J Med Chem, 2011, 46(4):1027-1039.
[10] KLUPP E M, BOTH A, BELMAR CAMPOS C, et al. Tedizolid susceptibility in linezolid-and vancomycin-resistant Enterococcus faecium isolates[J]. Eur J Clin Microbiol Infect Dis, 2016, 35(12):1957-1961.
[11] HOWE R A, WOOTTON M, NOEL A R, et al. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid[J]. Antimicrob Agents Chemother, 2003, 47(11):3651-3652.
[12] EDNIE L M, RATTAN A, JACOBS M R, et al. Antianaerobe activity of RBX 7644(ranbezolid), a new oxazolidinone, compared with those of eight other agents[J]. Antimicrob Agents Chemother, 2003, 47(3):1143-1147.
[13] GORDEEV M F, LUEHR G W, PATEL D V, et al. Preparation of N-acyl-3-aryl-2-oxooxazolidine-5-methanammines as bactericides:WO, 2001009107[P]. 2000-07-26.
[14] JADHAVAR P S, VAJA M D, DHAMELIYA T M, et al. Oxazolidinones as anti-tubercular agents:discovery, development and future perspectives[J]. Curr Med Chem, 2015, 22(38):4379-4397.
[15] BARBACHYN M R, FORD C W. Oxazolidinone structure-activity relationships leading to linezolid[J]. Angew Chem Int Ed Engl, 2003, 42(18):2010-2023.
[16] DAS B, RUDRA S, YADAV A, et al. Synthesis and SAR of novel oxazolidinones:discovery of ranbezolid[J]. Bioorg Med Chem Lett, 2005, 15(19):4261-4267.
[17] XIN Q S, FAN H X, GUO B, et al. Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents[J]. J Med Chem, 2011, 54(21):7493-7502.
[18] LESHER G Y, FROELICH E J, GRUETT M D, et al. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents[J]. J Med Pharm Chem, 1962, 91:1063-1065.
[19] CORREIA S, POETA P, HÉBRAUD M, et al. Mechanisms of quinolone action and resistance:where do we stand?[J]. J Med Microbiol, 2017, 66(5):551-559.
[20] CROSS R M, MONASTYRSKYI A, MUTKA T S, et al. Endochin optimization:structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity[J]. J Med Chem, 2010, 53(19):7076-7094.
[21] MAIGNAN J R, LICHOROWIC C L, GIARRUSSO J, et al. ICI 56,780 Optimization:Structure-activity relationship studies of 7-(2-phenoxyethoxy)-4(1H)-quinolones with antimalarial activity[J]. J Med Chem, 2016, 59(14):6943-6960.
[22] OUAHROUCH A, IGHACHANE H, TAOURIRTE M, et al. Benzimidazole-1,2,3-triazole hybrid molecules:synthesis and evaluation for antibacterial/antifungal activity[J]. Arch Pharm (Weinheim), 2014, 347(10):748-755.
[23] KAROLI T, MAMIDYALA S K, ZUEGG J, et al. Structure aided design of chimeric antibiotics[J]. Bioorg Med Chem Lett, 2012, 22(7):2428-2433.
[24] ROBERTSON G T, BONVENTRE E J, DOYLE T B, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic:microbiology profiling studies with staphylococci and streptococci[J]. Antimicrob Agents Chemother, 2008, 52(7):2324-2334.
[25] POKROVSKAYA V, BELAKHOV V, HAINRICHSON M, et al. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics[J]. J Med Chem, 2009, 52(8):2243-2254.
[26] HUBSCHWERLEN C, SPECKLIN J L, SIGWALT C, et al. Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids[J]. Bioorg Med Chem, 2003, 11(10):2313-2319.
[27] GORDEEV M F, HACKBARTH C, BARBACHYN M R, et al. Novel oxazolidinone-quinolone hybrid antimicrobials[J]. Bioorg Med Chem Lett, 2003, 13(23):4213-4216.
[28] HUBSCHWERLEN C, SPECKLIN J L, BAESCHLIN D K, et al. Structure-activity relationship in the oxazolidinone-quinolone hybrid series:influence of the central spacer on the antibacterial activity and the mode of action[J]. Bioorg Med Chem Lett, 2003, 13(23):4229-4233.
[29] T·卡布思纳, A·达尔霍夫. 含噁唑烷酮-喹诺酮的联合疗法在治疗细菌感染中的应用:中国, CN105246476A[P]. 2016-01-13.
KAPSNER T, DALHOFF A. Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections:China, CN105246476A[P]. 2016-01-13. (in Chinese)
[30] 克里斯蒂安·哈伯舒兰, 菲利普·潘彻德, 克里斯汀·西格瓦尔特,等.作为抗菌化合物的恶唑烷酮-喹诺酮混合物:中国,CN101238135B[P]. 2011-05-11.
PANCHAUD P, SIGWALT C, HUBSCHWERLEN C, et al. Oxazolidinone-quinolone hybrids as antibacterial compounds:China, CN101238135B[P]. 2011-05-11. (in Chinese)
[31] ENDRES B T, BASSèRES E, ALAM M J, et al. Cadazolid for the treatment of Clostridium difficile[J]. Expert Opin Investig Drugs, 2017, 26(4):509-514.
[32] LOCHER H H, CASPERS P, BRUYÈRE T, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections[J]. Antimicrob Agents Chemother, 2014, 58(2):901-908.
[33] CHILTON C H, CROWTHER G S, BAINES S D, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection[J]. J Antimicrob Chemother, 2014, 69(3):697-705.
[34] RASHID M U, LOZANO H M, WEINTRAUB A, et al. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden[J]. Anaerobe, 2013, 20:32-35.
[35] RASHID M U, DALHOFF A, WEINTRAUB A, et al. In vitro activity of MCB3681 against Clostridium difficile strains[J]. Anaerobe, 2014, 28:216-219.
[36] LOCHER H H, SEILER P, CHEN X H, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections[J]. Antimicrob Agents Chemother, 2014, 58(2):892-900.
[37] LOUIE T, NORD C E, TALBOT G H, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection[J]. Antimicrob Agents Chemother, 2015, 59(10):6266-6273.
[38] BALDONI D, GUTIERREZ M, TIMMER W, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile:safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses[J]. J Antimicrob Chemother, 2014, 69(3):706-714.
[39] GEHIN M, DESNICA B, DINGEMANSE J. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection[J]. Int J Antimicrob Agents, 2015, 46(5):576-581.